Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Five RNAi-Related Patent Applications: May 3, 2007

Title: RNA Interference-Mediated Inhibition of XIAP Gene Expression Using Short Interfering Nucleic Acid
Numbers: 20070093437
Filed: Aug. 6, 2004 PCT Filed: Aug. 6, 2004
Lead Inventor: Bharat Chowrira, Sirna Therapeutics (Merck)
“This invention relates to compounds, compositions, and methods useful for modulating XIAP gene expression using short interfering nucleic acid molecules,” the patent application’s abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of XIAP gene expression and/or activity by RNA interference using small nucleic acid molecules.”

Title: Use of Eukaryotic Genes Affecting Spindle Formation or Microtubule Function During Cell Division for Diagnosis and Treatment of Proliferative Diseases
Numbers: 20070093438
Filed: Sept. 15, 2004 PCT Filed: Sept. 15, 2004
Lead Inventor: Christophe Echeverri, Cenix BioScience
The invention, the patent application’s abstract states, “relates to the significant functional role of several C. elegans genes and of their corresponding gene products in spindle formation or microtubule function during cell division that could be identified by means of RNA-mediated interference and to the identification and isolation of functional orthologs of said genes including all biologically functional derivatives thereof. The invention further relates to the use of said genes and gene products (including said orthologs) in the development or isolation of anti-proliferative agents, particularly their use in appropriate screening assays, and their use for diagnosis and treatment of proliferative and other diseases,” the abstract adds. “In particular, the invention relates to the use of small interfering RNAs derived from said genes for the treatment of proliferative diseases.”

Title: Medical Treatment
Numbers: 20070093440
Filed: July 27, 2006
Lead Inventor: Brian Robert Champion, Lorantis (Celldex Therapeutics)
The patent application, its abstract states, claims an “RNAi agent targets a component of a human Notch signalling pathway other than presenilin1 or presenilin2 by RNA interference to reduce expression of said component.”